These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 25949228)

  • 21. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.
    Cho KH; Hall WA; Gerbi BJ; Higgins PD; McGuire WA; Clark HB
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1133-41. PubMed ID: 10613305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
    Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?
    Yuce Sari S; Aktas BY; Kertmen N; Elmali A; Kilickap S; Karli Oguz K; Mut M; Erman M; Soylemezoglu F; Zorlu F; Yazici G
    Cureus; 2021 Jun; 13(6):e15852. PubMed ID: 34327080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
    Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
    J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External beam radiation dose escalation for high grade glioma.
    Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
    Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
    Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
    J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.
    Krystal J; Hanson D; Donnelly D; Atlas M
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30874. PubMed ID: 38234020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
    Kambe A; Kitao S; Ochiai R; Hosoya T; Fujii S; Kurosaki M
    J Neurooncol; 2024 Jan; 166(1):175-183. PubMed ID: 38165552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta-analysis and Systematic Review.
    Xu Y; Li Q; Ma HY; Sun T; Xiang RL; Di F
    J Clin Pharm Ther; 2020 Dec; 45(6):1363-1371. PubMed ID: 32598559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience.
    Clark GM; McDonald AM; Nabors LB; Fathalla-Shaykh H; Han X; Willey CD; Markert JM; Guthrie BL; Bredel M; Fiveash JB
    Neurooncol Pract; 2014 Dec; 1(4):172-177. PubMed ID: 26034629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.
    Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E
    J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies.
    Tsien C; Gomez-Hassan D; Ten Haken RK; Tatro D; Junck L; Chenevert TL; Lawrence T
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):328-32. PubMed ID: 15890571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
    Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy.
    Combs SE; Steck I; Schulz-Ertner D; Welzel T; Kulozik AE; Behnisch W; Huber PE; Debus J
    Radiother Oncol; 2009 Apr; 91(1):60-6. PubMed ID: 19285356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
    Beige A; Ghiringhelli F; Lecuelle J; Truntzer C; Truc G; Vincent J; Farah W; Borsotti F; Mazilu I; Ilie SM
    Anticancer Res; 2022 Dec; 42(12):5847-5858. PubMed ID: 36456149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.